echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Cross-border pharmaceutical companies re-ranked in 2020, with changes in the top three

    Cross-border pharmaceutical companies re-ranked in 2020, with changes in the top three

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    GlobalData, a data analytics and consulting firm, has released market capitalization rankings and changes for TOP20 innovative pharmaceutical companies in the first quarter of 2020The global top 20 drugmaker's total market capitalization fell 7.9 percent to about $2.6 trillion compared with the fourth quarter of the previous year.
    Judging from the ranking, there are not many multinational drug companies that maintain the growth momentumOf the TOP20, 13 fell in market capitalisation, with Bayer down 28.5 percent, followed by GlaxoSmithKline (16.7 percent), Amgen (16.5 percent), Pfizer (16.5 percent), Baxter (16.2 percent) and Mercado (15.7 percent).
    The top three have also changed, with Pfizer's new ranking dropping from "Big Brother" to fifth place, plummetingJohnson and Johnson, Roche and Novartis are the top three.
    Johnson and Johnson's market value fell 10 percent in the first quarter, but the company remained the leaderJohnson and Johnson also face many challenges, such as Remicade and the prostate cancer drug Zytiga, which have been hit by genericdrugs.
    Roche's new ranking was second, with a 3.6 per cent rise in market capitalisation in the first quarter of this year, linked to its anti-inflammatory drug ActemraRoche's recent earnings showed sales of Actemra rose 30 percent to SFr66m in the first quarterIn addition, Roche's contribution to the field of oncology is not untableAs the cancer drug continues to grow, Roche relies on the advantage of tumor pipeline to occupy the position of the tumor.
    Novartis is still firmly in the top three, the industry believes that it is closely related to its emphasis on research and development, especially Novartis in China has also developed strongly, the cancer advantage is also highlightedNovartis currently focuses on five key cancer areas: breast cancer, lung cancer, melanoma, kidney cancer and hematology.
    It is understood that from 2017, Novartis Oncology (China) is 1-3 new products or new indications per year at the rate of the introduction of a number of targeted treatment of innovative drugs into the Chinese market, the current introduction of innovative drugs include the treatment of bone marrow fibrosis czech guard, the treatment of advanced kidney cancer, the treatment of primary immunotype platelet reduction of Rifland and the treatment of non-small cell lung cancer.
    In addition, the more obvious change is that Bayer, GSK and Sanofi have dropped out of the top 10, with Bayer having dropped to 18th in the global standings.
    It's worth noting that in the first quarter of this year, only two pharmaceutical companies, Regenerative Dollar and Gilead Sciences, have grown by more than 10% Among them, the growth of the regenerative element reached 32.5%, mainly due to the anti-inflammatory drug Kevzara, which had been tested in two key clinical trials by the end of March The company is currently preparing an antibody mixture for summer clinical trials.
    Gilead's market capitalisation rose 14.5 per cent, mainly due to the company's remdesivir In early April, Gilead said it had accelerated production schedules for the drug and increased production to produce 1 million Redseveby by the end of the year However, the reported draft document says Redsewe's phase 3 randomized, controlled clinical trial in China has failed Gilead's shares fell more than 8 percent on the news In May, Gilead will release clinical data in the U.S and Europe that the industry believes could more directly affect Gilead's market value in the second quarter of this year.
    Overall, the first quarter of this year was challenging for big pharmaceutical companies, with the industry arguing that a cumulative 7.9 per cent fall in market capitalisation was not as bad as it seemed, but there is no doubt that competition among multinational drug companies will become more intense in the future.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.